Over the last decade, genetic characterization of T-cell acute lymphoblastic leukemia (T-ALL) has led to the identification of a variety of chromosomal abnormalities. In this study, we used array-comparative genome hybridization (array-CGH) and identified a novel recurrent 9q34 amplification in 33% (12/36) of pediatric T-ALL samples, which is therefore one of the most frequent cytogenetic abnormalities observed in T-ALL thus far. The exact size of the amplified region differed among patients, but the critical region encloses B4 Mb and includes NOTCH1. The 9q34 amplification may lead to elevated expression of various genes, and MRLP41, SSNA1 and PHPT1 were found significantly expressed at higher levels. Fluorescence in situ hybridization (FISH) analysis revealed that this 9q34 amplification was in fact a 9q34 duplication on one chromosome and could be identified in 17-39 percent of leukemic cells at diagnosis. Although this leukemic subclone did not predict for poor outcome, leukemic cells carrying this duplication were still present at relapse, indicating that these cells survived chemotherapeutic treatment. Episomal NUP214-ABL1 amplification and activating mutations in NOTCH1, two other recently identified 9q34 abnormalities in T-ALL, were also detected in our patient cohort. We showed that both of these genetic abnormalities occur independently from this newly identified 9q34 duplication.
Introduction
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 10-15% of pediatric ALL cases. Current intensive treatment schedules have improved outcome, as the 5 year relapse-free survival rate nearly reaches 75%. Further improvement of this survival rate will be expected by a better understanding of the pathogenesis of T-ALL and the mechanism of cellular resistance against chemotherapy, providing new rationales for therapeutic intervention. 1 Genetic analyses of this malignancy have elucidated an enormous heterogeneity in genetic aberrations including chromosomal translocations, deletions and amplifications. Most of these abnormalities cause aberrant expression of a specific set of helix-loop-helix transcription factors, for example, TAL1/SCL, TAL2, LYL1, LMO1, and LMO2; deregulate the expression of homeobox genes like HOX11/TLX1, HOXA10/HOXA11 and HOX11L2/TLX3; or lead to the generation of fusion genes like CALM-AF10.
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Some of these genetic defects are cryptic aberrations and for that reason remain undetected by conventional cytogenetics. New high-resolution cytogenetic techniques may therefore lead to the identification of novel abnormalities in pediatric T-ALL. One such technique is the array comparative genome hybridization (array-CGH) technique enabling genome-wide high-resolution screening to detect new chromosomal regions of deletion or amplification. [12] [13] [14] It has mainly been used thus far for genomic screening of solid tumors [15] [16] [17] [18] and its application in the genomic analysis of hematological malignancies is limited to a few studies. 19, 20 Episomal NUP214-ABL1 amplifications were recently detected in pediatric T-ALL, leading to an aberrant activation of the protein tyrosine kinase activity of ABL1. 21 For this, the genomic region from ABL1 to NUP214 is circularized to form a NUP214-ABL1 fusion gene. This phenomenon results in the formation of a variable number of episomes, not previously detected by conventional cytogenetics, and accounts for a novel genetic mechanism leading to the activation of a tyrosine kinase in cancer. The NUP214-ABL1 amplification, which is observed in about 5% of the T-ALL samples, is suggested to be associated with poor outcome, and patients may therefore benefit from additional treatment with imatinib, a tyrosine kinase inhibitor. 21 Recently, another ABL1 fusion was identified in a T-ALL patient with a cryptic t(9;14)(q34;q32). In that case, the constitutive activation of the ABL1 tyrosine kinase activity was established by the formation of an EML1-ABL1 fusion product. 22 Other abnormalities also involving the 9q34 region in T-ALL involve mutations in the NOTCH1 gene. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] A role for NOTCH1 in human T-ALL was previously postulated due to its involvement in the rare chromosomal translocation t(7;9)(q34;q34.3). 24 The identification of activating NOTCH1 mutations in more than 50% of human T-ALL samples, 23 suggests a much broader role for this gene in human T-cell leukemogenesis.
25 NOTCH1 is an early transcription factor that commits lymphoid progenitor cells towards T-cell development. It encodes for a dimer of the extracellular subunit (NEC) noncovalently bound to the transmembrane (NTM) subunit. Two specific dimerization regions (HD-N, HD-C) regulate the stable association between these subunits. NOTCH1 activation is initiated by ligand binding to NEC, leading to the release of intracellular NOTCH after successive proteolytic cleavages. Intracellular NOTCH translocates to the nucleus where it forms a complex that activates the transcription of various target genes, including HES-1, PRE-Ta, DELTEX-1 and P21. 26, 27 So far NOTCH1 mutations appear to be restricted to three hotspot domains: the HD-N, the HD-C and the PEST domain. It has been suggested that these mutations lead to ligand independent activation of this transmembrane receptor. 23 In the present study, we used array-CGH to identify a novel duplication involving the 9q34 region in 33% of pediatric T-ALL samples, which is one of the most frequent cytogenetic abnormalities observed in T-ALL thus far. The relevance of this new and recurrent abnormality in relation to other newly discovered abnormalities in the 9q34 genomic region, like NUP214-ABL1 amplification or activating mutations in NOTCH1, has been investigated.
Materials and methods

Patient samples
Viable frozen leukemic cell suspensions obtained from either bone marrow and/or peripheral blood samples at diagnosis from untreated children with T-ALL were collected from the Sophia Children's Hospital/Erasmus MC and the Dutch Childhood Oncology Group (DCOG). At diagnosis, informed consent of the patients and/or parents was obtained to use left-over material for research purposes. Leukemic cells were isolated and enriched from these samples as previously described. 28 All samples contained X90% leukemic cells, as determined morphologically by May-Grü nwald-Giemsa (Merck, Darmstadt, Germany)-stained cytospins. Cryopreserved cells were used for several procedures. For DNA and RNA extraction, a minimum of 5 Â 10 6 leukemic cells were lysed in Trizol reagent (Gibco BRL, Life Technologies, Breda, The Netherlands) and stored at À801C. A total of 25 Â 10 3 leukemic cells was used for cytospin preparations for fluorescence in situ hybridization (FISH) which were stored at À201C. For the preparation of metaphase slides a minimum of 5 Â 10 6 leukemic cells were cultured for 72 h in serum-free medium (JRH Biosciences, Kansas, USA) in the presence of IL7 (10 ng/ml) and IL2 (10 ng/ml), and harvested according to standard cytogenetic techniques.
Genomic DNA isolation, RNA extraction and cDNA synthesis Genomic DNA and total cellular RNA were isolated according to the manufacturers' protocol, with minor modifications as described previously. 28 The RNA concentration was quantified spectrophotometrically. Following a denaturation step of 5 min at 701C, 1 mg of RNA was reverse transcribed to single-stranded cDNA using a mix of random hexamers (2.5 mM) and oligo dT primers (20 nM). The RT reaction was performed in a total volume of 25 ml containing 0.2 mM of each dNTP (Amersham Pharmacia BioTech, Piscataway, NJ, USA), 200 U Moloney murine leukemia virus reverse transcriptase (M-MLV RT) (Promega, Madison, WI, USA) and 25 U RNAsin (Promega). Conditions for the reaction were 371C for 30 min, 421C for 15 min and 941C for 5 min. The obtained cDNA was diluted to a final concentration of 8 ng/ml and stored at À801C.
Array-comparative genome hybridization
Array-CGH analysis was performed in duplicate for each patient, using a dye-swap experimental design to minimize false positive results. Patient genomic DNA (2 mg) and male/ female reference DNA (2 mg) (Promega) were fragmented by sonification (VibraCell Model VC130, Sonics & Materials, Newtown, CT, USA), size-verified by agarose gel electrophoresis and labeled with Cy5 and Cy3 dyes according to standard random priming protocols (Bioprime Labeling Kit, Invitrogen, Carlsbad, CA, USA). The DNAs were combined, denatured, and applied to two separate 1 Mb GenomeChipt V1.2 Human BAC arrays (2632 BAC clones spotted on a single array; Spectral Genomics, Houston, TX, USA) according to the manufacturer's protocol. DNA hybridization and washes were performed as recommended, and the slides were scanned on a GenePix 4000B Microarray Scanner (Axon Instruments, Union City, CA, USA). Cy3 and Cy5 fluorescent intensities at each DNA spot were quantified by GenePix Pro 4.0 Microarray Image Analysis Software and the data were subsequently imported into SpectralWare software (Spectral Genomics). Background intensities were subtracted and initial fluorescent ratios were log 2 transformed. Data points 42 s.d. away from the population mean ratio were identified as 'outliers' and removed. This procedure was repeated until the data points were all within the 2 s.d.-established threshold. 29 Regression was performed against a ratio value of 1. Using such strict normalization procedures, including the requirement that the deviation occurs for both components of the dye-swap experiment, 29 some significant data points might be eliminated (i.e. false negatives), but increased confidence in defining abnormal data points is obtained. The ratios for each clone were subsequently plotted into chromosome-specific profiles. At this stage, known largescale copy number polymorphisms were not considered disease-related. 29 The cutoff fluorescence ratios used for detection of genomic gain or loss were 0.8 and 1.2. In addition, the aberration needed to be present in both dye-swapped experiments.
Fluorescence in situ hybridization validation experiments
BACs were obtained from BAC/PAC Resource Center (Children's Hospital, Oakland, USA). BAC DNAs were isolated using DNA MiniPrep plasmid kit (Promega) and labeled by nick translation with Spectrum Orange-dUTP (Vysis, IL, USA). ABL1 amplification was detected using the LSI BCR-ABL ES (Vysis) translocation probe. HOX11L2 translocations were identified with the TLX3 split signal probe (Dakocytomation, Glostrup, Denmark). The BAC clones RP11-408N14 (9p21.3) and RP11-91o4 (11q21) were used to identify del(9)(p21.3p23) and del(11)(q14.1q22.3) in T-ALL patient 1179, respectively. The BAC clones RP11-707o3 (NOTCH1) and RP11-576c12 (9q32) were used to identify the 9q34 duplication. The cases without 9q34 abnormalities were used to calculate the cutoff value for this probe combination for use in interphase nuclei. The cutoff value was defined as the mean plus three times the s.d. The cutoff value for the presence of three RP11-707o3 signals was 3 Fluorescence in situ hybridization analysis was performed on interphase and metaphase preparations from methanol/acetic acid cell suspensions stored at À201C. Cytospins and metaphase preparations prepared from cryopreserved cells were stored at À201C. Before use, they were thawed on ice for 60 min and fixated in methanol/acetic acid (3:1). Afterwards, the slides were pre-treated with RNAse and pepsin, and post-fixed with formaldehyde, before being denatured for 2 min 15 s in 70% formamide/2 Â SSC at 721C. Fluorescence in situ hybridization probes were denatured for 8 min at 721C and hybridized overnight at 371C in a moist chamber. Slides were washed in 50% formamide/2 Â SSC and 2 Â SSC at 501C, 4 min each. After dehydration through an ethanol series (70, 85 and 96%), they were mounted with antifade containing 4 0 6-diamino-2-phenyl 9q34 duplication in pediatric T-ALL P van Vlierberghe et al indol (DAPI) as counterstain. For each sample a minimum of 100 interphase cells were scored, as well as 10-25 metaphases if present. Images were captured using an epifluorescence microscope (Zeiss Axioplan 2, Sliedrecht, The Netherlands) using MacProbe software (version 4.3, Applied Imaging, Newcastle upon Tyne, UK).
Mutational screening of NOTCH1
Mutational screening of NOTCH1 was performed as previously described. 23 Briefly, exon 26, encoding the N terminal region of the HD domain of NOTCH1, was divided in two amplicons. Exon 27, encoding the C terminal region of the HD domain of NOTCH1, was amplified as one amplicon and exon 34, encoding the PEST domain of NOTCH1, was divided in three amplicons. Direct sequencing was performed on all of the generated PCR products.
Quantitative real-time reverse transcriptase-polymerase chain reaction RT-PCR (Taqman)
The mRNA expression levels of NOTCH1 and an endogenous housekeeping gene encoding for glyceraldehydes-3-phosphate dehydrogenase (GAPDH) as a reference were quantified using real-time polymerase chain reaction (PCR) analysis (TaqMan chemistry) as previously described. 28 The relative NOTCH1 mRNA expression level in each patient was calculated using the comparative cycle time (C t ) method, as previously described. 30 From this, the relative NOTCH1 expression level to the GAPDH level was calculated using the following equation:
Gene expression array analysis and statistics RNA integrity, processing and hybridization to the U133 plus 2.0 GeneChip oligonucleotide microarray (Affymetrix) was performed as described before. 31 Probe sets located in the 9q33-34 regions with raw fluorescent intensities that were threefold higher than the arbitrary background level of 50 were selected (78 probesets, reflecting 53 genes). For these probesets, the expression was calculated relatively to the median expression of GAPDH (six probesets) for each patient sample. The difference in gene expression levels for patients with and without the 9q34 duplication was evaluated using the MannWhitney U test (MWU).
Results
New recurrent aberration in pediatric T-ALL
To find new chromosomal imbalances in pediatric T-ALL possibly related to outcome or leukemogenesis, array-CGH analysis was performed on a selected cohort of 36 clinically and karyotypically well-characterized diagnostic patient samples (Table 1) . Array-CGH analysis led to the identification of all numerical chromosomal aberrations, amplifications and deletions that matched previous karyotypic data, confirming the reliability of this genome-wide screening-technique. Unlike conventional karyotyping, array-CGH allows a more precise determination of the size of the amplified or deleted regions. For example, the heterozygous deletion at 9p22-q21 in patient 1950 could be specified to the region between 9p21.3-p22 (BAC 89C2) and 9q21.11 (BAC 203L2; Figure 1a) . Within this area, the region covered by the BAC clones 408N14 and AL391117.8 was homozygous deleted, including the p15 INK4B -p16 INK4A loci that are frequently deleted in pediatric T-ALL. 32 In contrast to conventional cytogenetics, a gain of genomic material was detected at 9q34 in 33% (12/36) of our pediatric T-ALL cases by array-CGH (Figure 1a) . Some of these patients were also characterized by other chromosomal rearrangements involving HOX11L2 (patients 720 HOX11L2-, HOX11 -, MLL-, TAL1-, CALM-AF10 or cMYC-abnormalities (data not shown). The exact size of the 9q34 amplified region varied among patients (Figure 1b) . The largest region of amplification was flanked by the BAC clones 1M19 (9q33.3) and 417A4 (9q34.3), whereas the smallest region ranged from BAC clone 326L24 (9q34.13) to 48C17 (9q34.3). The common region of genomic gain therefore includes clones 153P4, 145E17, 92B21, 100C15 and 707O3, and therefore distally from the ABL1 and NUP214 genes at 9q34.12-q34.13 ( Figure 1b) .
The relative difference in hybridization in the array-CGH analysis between the patient and the control DNA was lower than anticipated for a single copy gain in all leukemic cells of the patient. We postulated that this amplification would be present in a sub-fraction of the total leukemic population. To determine the percentage of cells carrying the 9q34 amplification, interphase cells were analyzed by FISH using the probes RP11-707o3 (NOTCH1) located in the common region of genomic gain, and RP11-576c12 (9q32), situated outside the amplified region. Samples with the 9q34 amplification showed an additional 9q34.3-specific (RP11-707o3) hybridization signal in a minority of leukemic cells (Figure 2a and b) . Fluorescence in situ hybridization analysis on metaphase cells showed that patients with the 9q34 amplification had a duplication of the 9q34 region (Figure 2 ). The percentage of cells with a 9q34 duplication ranged from 17 to 39 percent of the leukemic population at diagnosis (Table 2) .
Clinical relevance of the 9q34 duplication in pediatric T-ALL
The 9q34 duplication was observed in 12 out of 36 patients (Table 2) , of which six patients relapsed (Table 1) . Relapse material was available for four of these patients (patients 335, 1179, 1933, 3247; Table 2 ). Fluorescence in situ hybridization analysis on the relapse samples using the same 9q34 specific BAC-probe (707O3) showed 9q34 duplication in about 20-25% of the leukemic cells for all four specimens (Table 2) . Array-CGH analysis on the relapse material from these four patients confirmed the presence of the 9q34 duplication in a subpopulation of cells in all four relapse samples (Figure 3a) .
The episomal amplification of NUP214-ABL1 and the 9q34 duplication are independent genetic events in pediatric T-ALL We then investigated the relationship between this 9q34 duplication and the recently identified NUP214-ABL1 amplification also involving the 9q34 region. We failed to detect the NUP214-ABL1 amplification in our array-CGH analysis, as no BAC clone covering this genomic region was present on the DNA chips. Therefore, the incidence of the episomal NUP214-ABL1 amplification in our patient cohort was determined by FISH analysis using the LSI BCR-ABL ES translocation probe. We 9q34 duplication in pediatric T-ALL P van Vlierberghe et al identified the episomal ABL1 amplification in 2 out of 36 samples (5.6%; Table 2 ). This genetic abnormality was also present as subclonal abnormality in a low percentage of leukemic cells (5 and 3%) at diagnosis (patients 1179, 2775; Table 2 ; Figure 3b ). Both patients also carried the 9q34 duplication in a subclone of the leukemic cells (Table 2) . These patients relapsed but relapse material was only available for patient 1179. In this patient, the episomal amplification of NUP214-ABL1 was detected in 81% of the leukemic population at relapse (Figure 3c ). In contrast, the 9q34 duplication was present in only 22% of the leukemic cells ( Table 2 ), suggesting that none of the leukemic cells carried both genetic abnormalities simultaneously. Fluorescence in situ hybridization analysis on diagnosis and relapse material of patient 1179 using the ABL1-and a NOTCH1 probes simultaneously confirmed that the ABL1 amplification and the 9q34 duplication were present in separate leukemic cells (data not shown).
Identification of novel NOTCH1 mutations in pediatric T-ALL
Thirty out of 36 pediatric T-ALL samples were screened for the presence of mutations in the three hot spot regions of NOTCH1 involving exon 26 (HD-N), exon 27 (HD-C) and exon 34 (PEST). Seventeen NOTCH1 mutations were identified in 16 out of 30 T-ALL samples (53%; Table 2 ). The majority of mutations were located in exon 26. Only one patient had a mutated exon 27 and four patients showed a mutation in exon 34. Ten out of 17 mutations were novel mutations, whereas seven were identical [4] .isht(5;14)(q33;q32) 1179_R M 17, 9 46,XY,der(6)t(6;8)(q26;q24),del(8)(q24), del(9)(p21p21),der(9)del(9)(p21p21)add(9)(q11), del(11)(q21q23) [6] /46,idem,der(3;9)(p10;q10), der(6)t(3;6)(q29;p25),+del (9) 9q34 duplication in pediatric T-ALL P van Vlierberghe et al to mutations previously described. 23, 33 A leucine to proline conversion was observed most frequently (five of 17 mutations (29%)) at residues 1586, 1594, 1601 and 1679. Deletion of (GTG) at residue 1579 was observed in two patient samples. One patient showed two NOTCH1 mutations, both in the HD-N and PEST domains (patient 2738). Unfortunately, lack of patient material hampered confirmation whether both mutations occurred in cis. As only five out of 10 T-ALL samples with evidence for the 9q34 duplication, carried mutations in the NOTCH1 gene (Table 2) , no significant correlation between NOTCH1 mutations and the presence of a 9q34 duplicated subclone could be proven. Patients with or without a NOTCH1 mutation had comparable relapse rates (44 vs 53%, respectively).
Quantitative real-time PCR was used to measure the mRNA expression levels of NOTCH1 in pediatric T-ALL samples (Table 2) . No evidence for altered NOTCH1 expression levels in 9q34 duplicated patient samples was found (Table 2) . Besides, the NOTCH1 gene, the critical region enclosed VAV2 and TRAF2 and many other genes. Based upon raw fluorescent intensities from micro-array data, we then tested whether specific genes located in the 9q34 region were deregulated as consequence of the 9q34 duplication. For 21 pediatric T-ALLs, including seven patients with a subclonal 9q34 duplication, the expression levels for 78 probesets reflecting 53 genes located in the 9q33-34 region were calculated relative to the median GAPDH expression level. Whereas we did not find evidence for expression for VAV2 and TRAF2, three genes were identified that were significantly expressed at higher levels in patients with a 9q34-duplication compared to patients without the 9q34 duplication. These genes are MRPL41 (median expression of 8.6 vs 3.4%; MWU P ¼ 0.004), SSNA1 (median expression of 5.8 vs 4.1%; MWU P ¼ 0.009) and PHPT1 (median expression of 10.3 vs 6.9%; MWU P ¼ 0.01).
Discussion
In the present study, 36 pediatric T-ALL samples were screened by array-CGH analysis. The most frequent abnormality detected was a 9q34 duplication, present in a subpopulation of the leukemic cells in 33% of our patients. In a recent polymorphism study 29 using the same type of array-CGH slides and the same reference DNA, the 9q34 duplication has never been observed in over 200 healthy individuals (Personal communication, Dr Charles Lee, Dr John Iafrate), excluding the possibility that this 9q34 duplication is a polymorphism. This subclonal abnormality was observed in patients that were characterized by clonal abnormalities including the HOX11L2, HOX11, TAL1 or cMYC genes, so the 9q34 duplication seems not restricted to a specific cytogenetic T-ALL subgroup. The high incidence makes this chromosomal aberration one of the most frequent cytogenetic abnormalities in pediatric T-ALL. The critical genomic region covers various genes of which some have been previously linked to leukemogenesis like NOTCH1.
The NOTCH1 gene has previously been implicated with human T-ALL, due to its involvement in a rare translocation coupling NOTCH1 to the TCR-b locus. 24 Recently a broader role for NOTCH1 was suggested as 50% of T-ALL cases carry an activating mutation in one of the three hot-spots. 23 This is confirmed in our independent cohort of T-ALL patients of whom 53% had NOTCH1 mutations. Ten of the observed mutations were not previously described. 23, 33 Two NOTCH1 mutations (in exon 26 and exon 34) were simultaneously present in one patient (2738). This is of particular interest because mutations in cis may lead to an enhanced NOTCH1 activity 20-to 40-fold. 23 Patients, harboring NOTCH1 mutations, were randomly distributed throughout our pediatric T-ALL cohort, without any relationship with the 9q34 duplication.
In our cohort, the presence of a leukemic subclone containing the 9q34 duplication did not seem to affect clinical outcome. Six patients that carried this 9q34 duplication had relapsed, and four of these patients showed persistent leukemic cells at relapse with this duplication. This suggests that this leukemic subclone had actually survived intensive chemotherapeutic treatment. So, the presence of the 9q34 duplication may be associated with resistance to chemotherapeutic agents. As leukemic cells with the 9q34 duplication reflected a leukemic subclone at relapse in all four patients analyzed, it obviously does not provide a survival and/or proliferation advantage, or only provides a limited survival advantage but the subclone was just being overgrown by another subclone with a stronger survival/proliferation advantage as may be the case for patient 1179.
We also investigated a possible relationship with the newly identified NUP214-ABL1 episomal amplification and our 9q34 duplication. In two patients with the 9q34 duplication who relapsed, evidence was found for the presence of an episomal NUP214-ABL1 amplification at diagnosis in a low percentage of leukemic cells as well. In patient 1179, the leukemic subclone having the episomal ABL1 amplification had increased from 5% at diagnosis to B80% at relapse, implying that the episomal NUP214-ABL1 amplification may indeed be a poor prognostic marker as previously suggested. 9q34 duplication in pediatric T-ALL P van Vlierberghe et al
The subclonal 9q34 duplication seems not associated with mutations in NOTCH1, elevated NOTCH1 expression or episomal NUP214-ABL1 amplification. Analysis of microarray data for expressed genes located in the 9q33-34 regions revealed that the relative expression levels of MRLP41, SSNA1 and PHPT1 were about twofold elevated in 9q34 duplicated T-ALL cases. All three genes are situated in or just flanking the common region of duplication. SSNA1 encodes a nuclear autoantigen that is detected in patients with the Sjogren's syndrome, a chronic autoimmune disorder. 34 PHPT1 encodes a phosphohistidine phosphatase, whereas MRLP41 is translated into a mitochondrial ribosomal protein. None of these genes have been implicated in leukemogenesis before. The 9q34 duplication represent a minor leukemic clone, making it technically almost impossible to prove activation of specific genes located in the common duplicated region. It is therefore at present unclear whether these three genes are specifically activated or that also other genes in this region are activated as well.
In conclusion, we report the identification of a novel recurrent 9q34 duplication in 33 percent of pediatric T-ALL. The exact size of the amplified region differed slightly among patients, but the critical region encloses many genes including NOTCH1. This duplication appears to be an independent genetic event from both the episomal NUP214-ABL1 amplification 21 and the NOTCH1 mutations, 23 but may lead to the activation of References. 23,33 d Relative mRNA expression of NOTCH1 to GAPDH (%).
9q34 duplication in pediatric T-ALL P van Vlierberghe et al MRLP41, SSNA1 and PHPT1. The 9q34 duplicated leukemic subclone was still present at relapse in four patients analyzed, indicating that the 9q34 may provide cellular resistance towards chemotherapy.
